NCT06284317 (ADOPT-lung) is a Phase 3 clinical trial of Adjuvant durvalumab in Non Small Cell Lung Cancer, sponsored by ETOP IBCSG Partners Foundation.

Who is sponsoring NCT06284317?

NCT06284317 is sponsored by ETOP IBCSG Partners Foundation.

What drugs are being tested in NCT06284317?

Interventions in NCT06284317: Adjuvant durvalumab.

What condition does NCT06284317 study?

NCT06284317 studies Non Small Cell Lung Cancer.

Is NCT06284317 still recruiting?

NCT06284317 is currently recruiting now. Last updated 12 May 2026.

Last reviewed 2026-05-12 · How we verify

NCT06284317: ADOPT-lung

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC

Recruiting now Phase 3 Last updated 12 May 2026

What this trial tests

Phase 3 trial testing Adjuvant durvalumab in Non Small Cell Lung Cancer in 290 participants. Currently enrolling.

Timeline

15 January 2025

Primary endpoint
1 October 2029

1 March 2030

Quick facts

Lead sponsor	ETOP IBCSG Partners Foundation
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	290
Start date	15 January 2025
Primary completion	1 October 2029
Estimated completion	1 March 2030
Sites	42 locations across Australia, Austria, Belgium, Estonia, France, Ireland, Italy, Netherlands

Drugs / interventions tested

Adjuvant durvalumab — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

ETOP IBCSG Partners Foundation

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Disease-free survival (DFS)
Time frame: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Assessed in the adjuvant treatment phase. DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment w

Sponsor's own description

ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of ctDNA for Diagnosis and Histological Prediction in Early Stage Non-Small-Cell Lung Cancer: A Narrative Review.
Sassorossi C, Evangelista J, Stefani A, Chiappetta M, et al · · 2025 · cited 8× · PMID 40218254 · DOI 10.3390/diagnostics15070904
Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy.
Ohara S, Suda K, Tsutani Y. · · 2025 · cited 3× · PMID 40940723 · DOI 10.3390/cells14171312
Global advances and future directions in lung cancer care: expert consensus and strategic priorities.
Meyer ML, Peters S, Jänne PA, Mok TS, et al · · 2026 · cited 1× · PMID 41579430 · DOI 10.1016/j.esmoop.2025.106034
Neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer: Evidence to date and remaining questions.
Werner RS, Steinmann N, Opitz I. · · 2026 · PMID 41960128 · DOI 10.1016/j.xjon.2025.101577
Perioperative chemo immunotherapy in non-small-cell lung cancer: what can we learn from the long-term results of NADIM?
Fremand X, Onorati I, Duchemann B. · · 2025 · PMID 41367577 · DOI 10.21037/tlcr-2025-883
The role of immunotherapy in resectable non-small-cell lung cancer.
Moloney CD, Forde PM. · · 2025 · PMID 40861315 · DOI 10.1177/17588359251361883
Advances and Future Perspectives for the Management of Non-Small Cell Lung Cancer in Australia: A Narrative Review.
Brown LJ, Meredith G, Gao B, Ding P, et al · · 2026 · PMID 40851511 · DOI 10.1111/ajco.70001
Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer.
Kuhlman JJ, Li S, Manochakian R, Lou Y, et al · · 2024 · PMID 39764421 · DOI 10.37349/etat.2024.00281

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other ETOP IBCSG Partners Foundation trials

Trials by the same sponsor.

NCT05718297 — Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer · Phase 2 · withdrawn
NCT05896566 — A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients Wi · Phase 2 · completed
NCT05601973 — Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progressio · Phase 2 · active not recruiting
NCT04908956 — Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) · Phase 2 · terminated
NCT04245085 — ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06284317 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ETOP IBCSG Partners Foundation
Last refreshed: 12 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06284317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing